RU2622015C2 - Способ лечения пролиферативного заболевания - Google Patents

Способ лечения пролиферативного заболевания Download PDF

Info

Publication number
RU2622015C2
RU2622015C2 RU2014117707A RU2014117707A RU2622015C2 RU 2622015 C2 RU2622015 C2 RU 2622015C2 RU 2014117707 A RU2014117707 A RU 2014117707A RU 2014117707 A RU2014117707 A RU 2014117707A RU 2622015 C2 RU2622015 C2 RU 2622015C2
Authority
RU
Russia
Prior art keywords
treatment
weeks
braf
braf inhibitor
mutation
Prior art date
Application number
RU2014117707A
Other languages
English (en)
Russian (ru)
Other versions
RU2014117707A (ru
Inventor
Даррин Стьюарт
Мегхна Дас ТХАКУР
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of RU2014117707A publication Critical patent/RU2014117707A/ru
Application granted granted Critical
Publication of RU2622015C2 publication Critical patent/RU2622015C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2014117707A 2011-11-11 2012-11-09 Способ лечения пролиферативного заболевания RU2622015C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161558619P 2011-11-11 2011-11-11
US61/558,619 2011-11-11
PCT/US2012/064269 WO2013070996A1 (en) 2011-11-11 2012-11-09 Method of treating a proliferative disease

Publications (2)

Publication Number Publication Date
RU2014117707A RU2014117707A (ru) 2015-12-20
RU2622015C2 true RU2622015C2 (ru) 2017-06-08

Family

ID=47279036

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014117707A RU2622015C2 (ru) 2011-11-11 2012-11-09 Способ лечения пролиферативного заболевания

Country Status (10)

Country Link
US (1) US11007194B2 (enExample)
EP (1) EP2776037B1 (enExample)
JP (1) JP6150813B2 (enExample)
CN (2) CN103917236A (enExample)
AU (1) AU2012335663B2 (enExample)
BR (1) BR112014011223A8 (enExample)
CA (1) CA2855243C (enExample)
MX (1) MX354725B (enExample)
RU (1) RU2622015C2 (enExample)
WO (1) WO2013070996A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
RS58734B1 (sr) * 2012-08-07 2019-06-28 Novartis Ag Farmaceutske kombinacije koje obuhvataju b-raf inhibitor, egfr inhibitor i opciono pi3k-alfa inhibitor
FI3463345T3 (fi) * 2016-06-03 2023-01-31 Farmaseuttisia yhdistelmiä
US11590133B2 (en) * 2016-12-11 2023-02-28 Memorial Sloan Kettering Cancer Center Methods and compositions for treatment of BRAF mutant cancers
US12076320B2 (en) 2018-07-12 2024-09-03 Shenzhen Targetrx, Inc. Diarylpyrazole compound, composition comprising same, and use thereof
TWI817018B (zh) 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 用於治療ｂｒａｆ相關的疾病和失調症之化合物
TW202140011A (zh) * 2020-01-07 2021-11-01 美商銳新醫藥公司 Shp2抑制劑給藥和治療癌症的方法
CR20220626A (es) 2020-06-09 2023-01-23 Array Biopharma Inc Compuestos para el tratamiento de enfermedades y trastornos asociados a braf
WO2023230554A1 (en) 2022-05-25 2023-11-30 Pfizer Inc. Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer
EP4447956B1 (en) 2023-03-09 2025-04-30 Minneamrita Therapeutics LLC Drug combination for the treatment of stomach cancer
WO2025003956A1 (en) 2023-06-30 2025-01-02 Pfizer Inc. High drug loading formulations of encorafenib

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2402602C1 (ru) * 2009-02-12 2010-10-27 Государственное учреждение Российский онкологический научный центр им. Н.Н. Блохина РАМН КЛЕТОЧНАЯ ЛИНИЯ МЕЛАНОМЫ ЧЕЛОВЕКА mel Rac, ИСПОЛЬЗУЕМАЯ ДЛЯ ПОЛУЧЕНИЯ ПРОТИВООПУХОЛЕВЫХ ВАКЦИН
WO2011025927A1 (en) * 2009-08-28 2011-03-03 Irm Llc Compounds and compositions as protein kinase inhibitors

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391636B1 (en) 1994-05-31 2002-05-21 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US6358932B1 (en) 1994-05-31 2002-03-19 Isis Pharmaceticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US6037136A (en) 1994-10-24 2000-03-14 Cold Spring Harbor Laboratory Interactions between RaF proto-oncogenes and CDC25 phosphatases, and uses related thereto
US5717100A (en) 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
EE9900527A (et) 1997-05-22 2000-06-15 G.D. Searle & Co. Substitueeritud pürasoolid kui p38 kinaasi inhibiitorid
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US6204467B1 (en) 1998-03-24 2001-03-20 Ford Global Technologies, Inc. Method and apparatus for resistive welding
RU2319693C9 (ru) 1999-01-13 2008-08-20 Байер Копэрейшн Производные мочевины (варианты), фармацевтическая композиция (варианты) и способ лечения заболевания, связанного с ростом раковых клеток (варианты)
US6316435B2 (en) 1999-02-24 2001-11-13 Supergen, Inc. Combination therapy for lymphoproliferative diseases
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
BR0213486A (pt) 2001-10-25 2005-05-10 Novartis Ag Combinações que compreendem um inibidor seletivo de ciclooxigenase-2
EP1456180B1 (en) 2001-12-21 2007-10-03 Vernalis (Cambridge) Limited 3-(2,4)dihydroxyphenyl-4-phenylpyrazoles and their medical use
EA200600495A1 (ru) 2003-09-23 2006-10-27 Новартис Аг Комбинация ингибитора vegf рецептора с химиотерапевтическим агентом
CA2545942C (en) 2003-11-14 2012-07-10 Lorus Therapeutics Inc. Aryl imidazoles and their use as anti-cancer agents
US20090149469A1 (en) 2004-01-09 2009-06-11 Carlos Garcia-Echeverria Phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yl]-amine derivatives as igf-ir inhibitors
JP4688876B2 (ja) 2004-06-10 2011-05-25 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物
AU2006227447A1 (en) 2005-03-17 2006-09-28 Novartis Ag N- [3- (1-amin0-5, 6, 7, 8-tetrahydro-2 , 4, 4b-triazafluoren-9-yl)-phenyl] benzamides as tyrosine/threonine kinase inhibitors, in particular b-RAF kinase
US20070099856A1 (en) * 2005-05-13 2007-05-03 Gumerlock Paul H Combined treatment with docetaxel and an epidermal growth factor receptor kinase inhibitor using an intermittent dosing regimen
JP5178515B2 (ja) 2005-08-12 2013-04-10 シンタ ファーマシューティカルズ コーポレーション Ｈｓｐ９０活性を調節するピラゾール化合物
EP1919460A2 (en) 2005-08-22 2008-05-14 Novartis AG Pharmaceutical compositions comprising a ph-dependent drug, a ph modifier and a retarding agent
US20080242667A1 (en) 2005-08-26 2008-10-02 Smithkline Beecham Corporation Pyrimidinyl-Pyrazole Inhibitors of Aurora Kinases
TWI387592B (zh) 2005-08-30 2013-03-01 Novartis Ag 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法
JP2009530261A (ja) 2006-03-16 2009-08-27 ファイザー・プロダクツ・インク ピラゾール化合物
CN101415411A (zh) 2006-04-05 2009-04-22 诺瓦提斯公司 用于治疗癌症的治疗剂组合
WO2007123892A2 (en) 2006-04-17 2007-11-01 Arqule Inc. Raf inhibitors and their uses
CA2663366C (en) 2006-10-02 2012-02-07 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2008045627A2 (en) 2006-10-06 2008-04-17 Irm Llc Protein kinase inhibitors and methods for using thereof
EP2491923A3 (en) 2007-02-15 2012-12-26 Novartis AG Combinations of therapeutic agents for treating cancer
US20090022789A1 (en) 2007-07-18 2009-01-22 Supernus Pharmaceuticals, Inc. Enhanced formulations of lamotrigine
CA2695114A1 (en) 2007-08-01 2009-02-05 Pfizer Inc. Pyrazole compounds and their use as raf inhibitors
CA2699301A1 (en) 2007-10-19 2009-04-23 Abbott Gmbh & Co. Kg Solid dispersion product of n-aryl urea-based drugs
US8785486B2 (en) 2007-11-14 2014-07-22 Janssen Pharmaceuticals, Inc. Imidazo[1,2-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
EA201001456A1 (ru) 2008-03-21 2011-06-30 Новартис Аг Новые гетероциклические соединения и их применение
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
DK2324008T3 (da) 2008-07-24 2012-07-23 Nerviano Medical Sciences Srl Diarylpyrazol som protein kinase inhibitorer
US8088771B2 (en) 2008-07-28 2012-01-03 Gilead Sciences, Inc. Cycloalkylidene and heterocycloalkylidene inhibitor compounds
CN102227421A (zh) 2008-09-29 2011-10-26 贝林格尔.英格海姆国际有限公司 抗增殖化合物
DK2346495T4 (da) 2008-10-07 2023-08-28 Kudos Pharm Ltd Farmaceutisk formulering 514
WO2010056662A1 (en) 2008-11-11 2010-05-20 University Of Washington Activated wnt-beta-catenin signaling in melanoma
WO2010070060A1 (en) 2008-12-19 2010-06-24 Nerviano Medical Sciences S.R.L. Bicyclic pyrazoles as protein kinase inhibitors
AR075180A1 (es) 2009-01-29 2011-03-16 Novartis Ag Formulaciones orales solidas de una pirido-pirimidinona
WO2010100127A1 (en) 2009-03-04 2010-09-10 Novartis Ag Disubstituted imidazole derivatives as modulators of raf kinase
TWI532484B (zh) 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑
EP3045457B1 (en) 2009-06-15 2018-05-09 Nerviano Medical Sciences S.r.l. Substituted pyrimidinylpyrrolopyridinone derivatives, process for their preparation and their use as kinase inhibitors
KR101256018B1 (ko) 2009-08-20 2013-04-18 한국과학기술연구원 단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물
US8242260B2 (en) 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
CN102947290B (zh) 2010-01-27 2015-05-27 内尔维安诺医学科学有限公司 作为蛋白激酶抑制剂的3,4-二芳基吡唑的亚磺酰氨基衍生物
SG184243A1 (en) 2010-03-30 2012-10-30 Verseon Corp Multisubstituted aromatic compounds as inhibitors of thrombin
EP2601185B1 (en) 2010-08-03 2015-10-07 Nerviano Medical Sciences S.r.l. Derivatives of pyrazolophenyl-benzenesulfonamide compounds and use thereof as antitumor agents
US20140093565A1 (en) 2011-03-21 2014-04-03 Valcuria Ab A pharmaceutical composition comprising a hdac inhibitor and a steroid and the use thereof
US20140113919A1 (en) 2011-06-14 2014-04-24 Novartis Ag Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm
CN103945831A (zh) 2011-11-23 2014-07-23 诺华股份有限公司 医药制剂
RU2015121367A (ru) 2012-11-08 2017-01-10 Новартис Аг Фармацевтическая комбинация, содержащая ингибитор b-raf и ингибитор деацетилазы гистонов, и ее применение при лечении пролиферативных заболеваний

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2402602C1 (ru) * 2009-02-12 2010-10-27 Государственное учреждение Российский онкологический научный центр им. Н.Н. Блохина РАМН КЛЕТОЧНАЯ ЛИНИЯ МЕЛАНОМЫ ЧЕЛОВЕКА mel Rac, ИСПОЛЬЗУЕМАЯ ДЛЯ ПОЛУЧЕНИЯ ПРОТИВООПУХОЛЕВЫХ ВАКЦИН
WO2011025927A1 (en) * 2009-08-28 2011-03-03 Irm Llc Compounds and compositions as protein kinase inhibitors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PIZZOLATO N. et al. Stochastic dynamics of leukemic cells under an intermittent targeted therapy// Theory Biosci. 2011 Sep;130(3):203-10. TOMASETTI C. et al. An elementary approach to modeling drug resistance in cancer// Math Biosci Eng. 2010 Oct;7(4):905-18. *
ЧИССОВ В.И. и др. "Онкология. Национальное руководство"//М., ГЭОТАР-Медиа, с.848-862. *
ЧИССОВ В.И. и др. "Онкология. Национальное руководство"//М., ГЭОТАР-Медиа, с.848-862. PIZZOLATO N. et al. Stochastic dynamics of leukemic cells under an intermittent targeted therapy// Theory Biosci. 2011 Sep;130(3):203-10. TOMASETTI C. et al. An elementary approach to modeling drug resistance in cancer// Math Biosci Eng. 2010 Oct;7(4):905-18. *

Also Published As

Publication number Publication date
CA2855243A1 (en) 2013-05-16
US11007194B2 (en) 2021-05-18
EP2776037A1 (en) 2014-09-17
JP6150813B2 (ja) 2017-06-21
MX2014005726A (es) 2014-05-28
AU2012335663A1 (en) 2014-05-29
CA2855243C (en) 2020-04-14
WO2013070996A1 (en) 2013-05-16
CN108542906A (zh) 2018-09-18
AU2012335663B2 (en) 2015-12-24
BR112014011223A2 (pt) 2017-05-09
EP2776037B1 (en) 2019-01-09
MX354725B (es) 2018-03-16
RU2014117707A (ru) 2015-12-20
JP2014533272A (ja) 2014-12-11
CN103917236A (zh) 2014-07-09
BR112014011223A8 (pt) 2023-01-31
US20140275136A1 (en) 2014-09-18
HK1198920A1 (en) 2015-06-19

Similar Documents

Publication Publication Date Title
RU2622015C2 (ru) Способ лечения пролиферативного заболевания
He et al. Mechanisms and management of 3rd‑generation EGFR‑TKI resistance in advanced non‑small cell lung cancer
US20240299388A1 (en) Erk1/2 and shp2 inhibitors combination therapy
Furukawa Molecular targeting therapy for pancreatic cancer: current knowledge and perspectives from bench to bedside
JP2019532051A5 (enExample)
Hofmann et al. Molecular mechanisms of resistance to kinase inhibitors and redifferentiation in thyroid cancers
Naraev et al. Current status and perspectives of targeted therapy in well-differentiated neuroendocrine tumors
US20190134034A1 (en) Method of Treating Liver Cancer
MG Saez Treatment directed to signalling molecules in patients with advanced differentiated thyroid cancer
Ding et al. Multitarget inhibitors derived from crosstalk mechanism involving VEGFR2
Ho et al. Cancer Management by Tyrosine Kinase Inhibitors: Efficacy
JP2018502089A5 (enExample)
US11406627B2 (en) Combinations of MDM2 inhibitors with inhibitors of ERK for treating cancers
US20250120978A1 (en) Jak inhibitor with erk1/2 and/or shp2 inhibitors combination therapy
HK1198920B (en) Method of treating a proliferative disease
Pasqualetti et al. The emerging role of sunitinib in the treatment of advanced epithelial thyroid cancer: our experience and review of literature
Khan et al. An Update on BRAF Inhibitors and Other new Molecular Targets for the Treatment of Malignant Melanoma of the skin
Palmieri et al. Resistance to targeted therapies in melanoma: new insights
CN117897158A (zh) Erk1/2和shp2抑制剂组合疗法
EP4358967A1 (en) Erk1/2 inhibitor combination therapy
CA3222730A1 (en) Erk1/2 and egfr inhibitors combination therapy
Hanaford USING A NOVEL HUMAN NEURAL STEM CELL MODEL OF AGGRESSIVE MEDULLOBLASTOMA TO INVESTIGATE NEW THERAPEUTIC STRATEGIES
PubChem et al. Mechanism of action
RU2019111662A (ru) Терапевтические комбинации, содержащие ингибитор raf и ингибитор erk

Legal Events

Date Code Title Description
PC41 Official registration of the transfer of exclusive right

Effective date: 20211005